[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gout-chronic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gout-chronic":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100621234","phase-1-drug-drug-interaction-study-of-abp-671-in-gout-patients-100621234",false,"NCT07367971","Drug-Drug Interaction Study of ABP-671 in Gout Patients","Open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients","Inclusion Criteria:\n\n* Adults 18-75 years with clinical diagnosis of gout.\n* Stable Allopurinol therapy QD for ≥14 days prior to Day 1.\n* Cohort N: Normal renal function.\n* Cohort R: Moderate renal impairment.\n\nExclusion Criteria:\n\n* Clinically significant hepatic impairment.\n* History of Allopurinol hypersensitivity.\n* Pregnancy or breastfeeding.","ALL","18 Years","75 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.",[27,28,29],"Gout Chronic","Gout","DDI (Drug-Drug Interaction)",[31,27,32],"gout","ABP-671","RECRUITING","2026-04-12",{"date":36,"type":37},"2026-04-14","ACTUAL",{"date":39,"type":37},"2026-01-23",{"date":41,"type":21},"2026-08-31",{"name":43,"class":44},"Atom Therapeutics Co., Ltd","INDUSTRY",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100597676","developing-a-gout-action-plan-in-primary-care-setting-in-singapore-100597676","NCT07061587","Developing A Gout Action Plan in Primary Care Setting in Singapore","For patient participants:\n\nInclusion Criteria:\n\n* Adults who are 21 years old and above\n* Clinical diagnosis of gout as per ACE-EULAR 2015 criteria\n* Had at least an episode of gout exacerbation within the last 1 year\n* Able to speak and read English\n* Singapore citizens or permanent residents\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Mental disorders\n* Cognitive impairment\n* Hearing and\u002F or speech impairments\n* Pregnant\n* Known terminal illness\n* Unable to provide informed consent\n\nFor healthcare professionals:\n\nInclusion Criteria (for healthcare professionals):\n\n* Currently still in clinical practice\n* Manage gout in their clinical practice\n\nExclusion Criteria (for healthcare professionals):\n\n* Not involved in gout management in the practice\n* No longer in clinical practice","21 Years",{"count":54,"type":21},72,[56],"NA","The goal of this clinical trial is to develop a gout action plan in primary care setting in Singapore among adult patients with gout, and to learn if the gout action plan can improve gout control.\n\nThe main questions it aims to answer are:\n\n* How do we develop a gout action plan in primary care setting in Singapore?\n* What is the feasibility and estimate effectiveness of the developed gout action plan?\n* Does gout action plan reduce frequency of gout flares in patients with gout?\n\nResearchers will compare gout action plan to usual clinical care to see whether gout action plan helps in improving gout control.\n\nParticipants in intervention arm will be:\n\n* given gout action plan and follow up for a course of 6 months\n* asked to keep track of their gout symptoms\n* follow up on the number of gout flares they have.",[59,60,27],"Gout; Hyperuricemia","Gout Flare",[62,63],"Gout action plan","action plan","NOT_YET_RECRUITING","2025-07-02",{"date":67,"type":37},"2025-07-11",{"date":69,"type":21},"2025-08",{"date":71,"type":21},"2027-07",{"name":73,"class":74},"SingHealth Polyclinics","OTHER",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100589628","phase-2-maintenance-or-withdrawal-of-urate-lowering-therapy-according-to-ultrasound-features-in-gout-patients-a-randomised-controlled-trial-stop-treatment-in-gout-100589628","NCT06956885","Maintenance or Withdrawal of Urate Lowering Therapy According to Ultrasound Features in Gout Patients: a Randomised Controlled Trial Stop Treatment In Gout","Maintenance or Withdrawal of Urate Lowering Therapy According to Ultrasound Features in Gout Patients: a Randomised Controlled Trial","STING","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Gout, defined according to the 2015 ACR\u002FEULAR classification criteria\n* No flares for at least 2 years\n* No tophi\n* Currently receiving allopurinol or febuxostat taken for at least 2 years and SUA levels ≤ 60 mg\u002Fl\n* No urate deposit on ultrasound at inclusion visit at both MTPs 1 and knees\n* Ability to provide informed consent\n* Women of childbearing potential (WOCBP) are required to have a negative pregnancy test before treatment and must agree to maintain during treatment highly effective contraception (ie,abstinence, combined estrogen- and progestogen-containing hormonal contraception, ovulation inhibitors (Oral, Intravaginal, Transdermal); Progestogen-only hormonal contraception associated with inhibition of ovulation (Oral, Injectable, Implantable); Intrauterine device (IUD); Intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomised partner).\n* Health Insurance\n\nExclusion Criteria:\n\n* Unstable systemic medical condition (e.g., New York Heart Association stage IV heart failure, recent myocardial infarction, advanced cancer)\n* History of allergy to allopurinol or febuxostat or one of the excipients\n* Association with azathioprine, mercaptopurine (cytostatics-antimetabolites)\n* Contraindications to experimental medicinal products or auxiliary medicinal products\n* CKD stage 4 (eGFR less than 30 ml\u002Fmn\u002F1.73 m2)\n* Ongoing treatment with uricosurics (benzbromarone and probenecid) or uricase\n* Patient on SMA (state medical aid-AME)\n* Participation in other clinical trial on medicinal product for human use\n* Lack of contraception for women of childbearing potential.",{"count":84,"type":21},450,[86],"PHASE2","According to international recommendations, urate lowering therapy (ULT), mainly the xanthine oxidase inhibitors (XOIs) allopurinol and febuxostat, should be prescribed lifelong in gout patients. However, this recommendation comes up against very poor adherence to ULT, since around half of patients stop their treatment at 5 years. Moreover, there is uncertainty about the cardiovascular tolerance of febuxostat taken over the long term. Finally, although XOIs are generally well tolerated, they can cause side effects and require regular biological monitoring. The hypothesis is that the risk of flares following withdrawal of ULT is very low in gout patients when urate store is depleted and repeated ultrasounds (US) do not demonstrate the reappearance of urate deposits.",[27],"2025-04-25",{"date":91,"type":37},"2025-05-04",{"date":93,"type":21},"2025-05-01",{"date":95,"type":21},"2030-05-01",{"name":97,"class":74},"Assistance Publique - Hôpitaux de Paris"]